Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Canaccord Genuity initiates coverage on Essensys

(Sharecast News) - Analysts at Canaccord Genuity initiated coverage on digital experience business Essensys with a 'buy' rating and a 41.0p target price on Tuesday as it said the group was looking to scale with strategics. Canaccord Genuity said a new Essensys was now emerging, with a new CEO, CFO, simplified go-to-market strategy, and a new, industry-first product, elumo.

While Canaccord said FY25-26 were "likely to be transition years", but noted the expected improvement in revenue mix and gross margins should return Essensys to profitability and cash generation in FY26.

Despite forecasts for declining FY25-26 revenues, Canaccord Genuity believes the route to cash generation to be underpinned by a "significant improvement" in revenue mix, a reduction in costs following the decommissioning of four of its 13 data centres in H125, and a group reorganisation that "should more than halve" operational expenditure by FY25.

"Essensys appears well-positioned to benefit from changes in the commercial real estate market due to the increasing demand for flexible office spaces and premium tenant experiences," said the Canadian bank.

"Essensys Platform and elumo provide landlords/operators with new monetisation mechanisms and provide greater insight into utilisation, enabling landlords to better predict churn."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.